P006 The DERIVO 2 heal embolization device in the treatment of ruptured and unruptured intracranial aneurysms: a retrospective multicenter study final results

<h3>Introduction</h3> The emerging use of flow diverters in the treatment of intracranial aneurysms is associated with a risk of neurological morbidity due to their thrombogenicity.^(1-3) The Derivo 2 Embolization Device (Acandis, Pforzheim, Germany) has proven to be a safe and effective flow diverter.^(4-5) To overcome the risk of thrombo-embolism, the device was modified by adding an anti-thrombogenic fibrin-heparin coating.^(6-7) <h3>Aim of Study</h3> We aimed to assess the safety and effectiveness of the Derivo 2 heal Embolization Device. <h3>Methods</h3> Retrospective multicenter data from nine German neurovascular centers between February 2022 until December 2023 were used. Patients treated with the Derivo 2 heal Embolization Device for unruptured or ruptured intracranial aneurysms were included. Peri- and postprocedural adverse events, clinical outcomes, and angiographic follow-up results were evaluated. <h3>Results</h3> 84 patients (73.8% female, mean age 58,7 years) with 89 aneurysms (mean size 9.76 mm) were included. 87.6% were located in the anterior circulation. Most of them were sidewall aneurysms (88.8%). 96 flow diverters were used. 99% were successfully implanted. An in-stent balloon angioplasty was performed in 6% of the cases. An additional coiling was performed in 28.6%. Technical difficulties were present in 12% of the cases. Thrombotic events occurred in 4.8% with no neurological sequelae. Mortality and morbidity were 0% and 1.2% respectively. Adequate aneurysm occlusion was achieved in 80.7% with a mean follow-up time of 6.6 months. <h3>Conclusion</h3> The Derivo 2 heal Embolization Device showed a satisfying aneurysm occlusion and safety with a low rate of neurological morbidity. <h3>Disclosure of Interest</h3> no.